NASDAQ:ATXI - Avenue Therapeutics News Headlines

$5.80
-0.08 (-1.36 %)
(As of 08/18/2019 03:05 PM ET)
Today's Range
$5.80
Now: $5.80
$5.96
50-Day Range
$5.68
MA: $6.04
$6.30
52-Week Range
$2.08
Now: $5.80
$7.98
Volume6,300 shs
Average Volume15,379 shs
Market Capitalization$96.05 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.41

Headlines

Avenue Therapeutics (NASDAQ ATXI) News Headlines

Source:
DateHeadline
Avenue Therapeutics (NASDAQ:ATXI) Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPSAvenue Therapeutics (NASDAQ:ATXI) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - August 15 at 12:44 PM
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 14 at 9:00 AM
Avenue Therapeutics Inc (NASDAQ:ATXI) CFO Joseph Walter Vazzano Sells 4,688 SharesAvenue Therapeutics Inc (NASDAQ:ATXI) CFO Joseph Walter Vazzano Sells 4,688 Shares
www.americanbankingnews.com - August 12 at 6:53 PM
Short Interest in Avenue Therapeutics Inc (NASDAQ:ATXI) Declines By 32.0%Short Interest in Avenue Therapeutics Inc (NASDAQ:ATXI) Declines By 32.0%
www.americanbankingnews.com - August 12 at 6:32 PM
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of DirectorsAvenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
finance.yahoo.com - August 1 at 11:22 AM
Avenue Therapeutics Inc (NASDAQ:ATXI) Short Interest Down 29.9% in JulyAvenue Therapeutics Inc (NASDAQ:ATXI) Short Interest Down 29.9% in July
www.americanbankingnews.com - July 27 at 10:49 AM
 Brokerages Expect Avenue Therapeutics Inc (NASDAQ:ATXI) Will Announce Earnings of -$0.57 Per Share Brokerages Expect Avenue Therapeutics Inc (NASDAQ:ATXI) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - July 27 at 2:18 AM
3 Foolproof Strategies To Minimize Risk3 Foolproof Strategies To Minimize Risk
finance.yahoo.com - June 8 at 9:30 AM
Avenue Therapeutics Trades Higher After Phase 3 SuccessAvenue Therapeutics Trades Higher After Phase 3 Success
finance.yahoo.com - June 3 at 5:43 PM
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative PainAvenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
finance.yahoo.com - June 3 at 9:37 AM
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 13 at 9:47 AM
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of DirectorsAvenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
finance.yahoo.com - April 30 at 9:36 AM
Plenty Of Further Upside In Fortress BiotechPlenty Of Further Upside In Fortress Biotech
seekingalpha.com - March 19 at 10:02 AM
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 12 at 11:06 AM
Earn Outsized Alpha With Avenue TherapeuticsEarn Outsized Alpha With Avenue Therapeutics
seekingalpha.com - February 7 at 9:44 AM
Topline data readout expected in mid-2019Topline data readout expected in mid-2019
globenewswire.com - December 19 at 9:44 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXISHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI
finance.yahoo.com - December 13 at 9:02 AM
ATXI: InvaGen Acquisition Spices Up Quarterly ReportATXI: InvaGen Acquisition Spices Up Quarterly Report
finance.yahoo.com - December 3 at 9:40 AM
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 15 at 9:25 AM
Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call (Transcript)Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call (Transcript)
seekingalpha.com - November 14 at 4:23 PM
ATXI: InvaGen Capital Raise & AcquisitionATXI: InvaGen Capital Raise & Acquisition
finance.yahoo.com - November 13 at 4:25 PM
Avenue Therapeutics up 31% premarket on takeover by InvaGenAvenue Therapeutics up 31% premarket on takeover by InvaGen
seekingalpha.com - November 13 at 9:11 AM
Avenue Therapeutics up 95% on dim Ad Com prospects for Trevenas oliceridineAvenue Therapeutics up 95% on dim Ad Com prospects for Trevena's oliceridine
seekingalpha.com - October 11 at 4:11 PM
Avenue Therapeutics down 15%Avenue Therapeutics down 15%
seekingalpha.com - September 17 at 4:22 PM
ATXI: Second Quarter 2018 ResultsATXI: Second Quarter 2018 Results
finance.yahoo.com - August 27 at 4:16 PM
Biotech incubator taps investors through in-house brokerageBiotech incubator taps investors through in-house brokerage
finance.yahoo.com - August 2 at 10:10 AM
Avenue Therapeutics Is On To SomethingAvenue Therapeutics Is On To Something
seekingalpha.com - June 26 at 11:23 AM
ATXI: KOL Call with Drs. Singla and Minkowitz on IV TramadolATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol
finance.yahoo.com - June 12 at 4:16 PM
Avenue Therapeutics up 32% premarket on positive late-stage results for pain med IV tramadolAvenue Therapeutics up 32% premarket on positive late-stage results for pain med IV tramadol
seekingalpha.com - May 21 at 9:27 AM
ATXI: 1Q:18 Update Confirms TimelineATXI: 1Q:18 Update Confirms Timeline
finance.yahoo.com - May 14 at 10:34 AM
ATXI: No Pain? We See a Gain; Developing TramadolATXI: No Pain? We See a Gain; Developing Tramadol
finance.yahoo.com - April 10 at 4:18 PM
Avenue Therapeutics to Present at March Investor ConferencesAvenue Therapeutics to Present at March Investor Conferences
finance.yahoo.com - March 5 at 9:57 AM
Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 1 at 9:21 AM
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor ConferenceAvenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:00 AM
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative PainAvenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain
finance.yahoo.com - January 2 at 8:50 AM
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate HighlightsAvenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 9 at 5:21 PM
Weekly Top Insider Buys Highlight for the Week of Oct. 13Weekly Top Insider Buys Highlight for the Week of Oct. 13
www.nasdaq.com - October 15 at 3:56 PM
Avenue Therapeutics (ATXI) Doses First Patient in Pivotal Phase 3 ... - StreetInsider.comAvenue Therapeutics (ATXI) Doses First Patient in Pivotal Phase 3 ... - StreetInsider.com
www.streetinsider.com - September 28 at 12:51 AM
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel